Background: Population-based studies represent the whole spectrum of patient population and should represent the mainstay when evaluating patients' prognosis. A high number of CD patients need surgical intervention during the disease course. The disease course of inflammatory bowel diseases, including ulcerative colitis (UC) and Crohn's disease (CD), is quite varied and still quite unpredictable. Key Messages: According to earlier studies, up to 60% of patients undergo at least one operation after 10 years of CD duration. Newer cohorts report lower cumulative probability of surgery of approximately 40% after 10 years. The colectomy rate in UC is approximately 10% after 10 years from diagnosis with a geographic difference. Similarly to CD, the colectomy rate seems to decrease over time. There is some evidence that the increasing use of immunosuppressive and/or biological therapy might have been responsible for this favourable trend. However, other factors may have an impact on decreasing surgical trend over time. The relative risk (RR) of colorectal cancer (CRC) in UC is approximately doubled compared to background population. However, the absolute risk in general is relatively low between 1.1 and 5.3% after 20 years of disease duration. Furthermore, a decreasing trend in the incidence of CRC has been reported in recent studies. Importantly, several factors such as disease extent, activity, age at UC onset, and so on may increase/modify an individual risk. Similar to UC, CD patients have approximately 2 times higher RR of cancer compared to background population. The risk is higher for colon than for rectum cancer and present only in CD patients with colonic involvement. Conclusions: The surgery rate in CD has decreased over the time period. The evidence on colectomy rate in UC is less conclusive. The RR of CRC in UC and CD is approximately doubled compared to that of the background population, but it seems to be decreasing in more recent cohorts.

Keywords:
Inflammatory bowel disease, Surgery, Immunosuppressive therapy, Biological therapy, Colorectal cancer
1.
Burisch J, Jess T, Martinato M, Lakatos PL; ECCO-EpiCom: The burden of inflammatory bowel disease in Europe. J Crohns Colitis 2013;7:322-337.
2.
Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B; Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD): Hospitalisations and surgery in Crohn's disease. Gut 2012;61:622-629.
3.
Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, et al: The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study 1989-2010. Am J Gastroenterol 2014;109:409-416.
4.
Rungoe C, Langholz E, Andersson M, Basit S, Nielsen NM, Wohlfahrt J, et al: Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011. Gut 2014;63:1607-1616.
5.
Frolkis AD, Dykeman J, Negrón ME, Debruyn J, Jette N, Fiest KM, et al: Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996-1006.
6.
Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al: Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut 2006;55:510-518.
7.
Frolkis AD, Lipton DS, Fiest KM, Negrón ME, Dykeman J, deBruyn J, et al: Cumulative incidence of second intestinal resection in Crohn's disease: a systematic review and meta-analysis of population-based studies. Am J Gastroenterol 2014;109:1739-1748.
8.
Hoie O, Wolters FL, Riis L, Bernklev T, Aamodt G, Clofent J, et al: Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology 2007;132:507-515.
9.
Jeuring SF, Bours PH, Zeegers MP, Ambergen TW, van den Heuvel TR, Romberg-Camps MJ, et al: Disease outcome of ulcerative colitis in an era of changing treatment strategies: results from the Dutch population-based IBDSL cohort. J Crohns Colitis 2015;9:837-845.
10.
Kaplan GG, Seow CH, Ghosh S, Molodecky N, Rezaie A, Moran GW, et al: Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol 2012;107:1879-1887.
11.
Samuel S, Ingle SB, Dhillon S, Yadav S, Harmsen WS, Zinsmeister AR, et al: Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis 2013;19:1858-1866.
12.
Chhaya V, Saxena S, Cecil E, Chatu S, Subramanian V, Curcin V, et al: The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009. Aliment Pharmacol Ther 2015;41:87-98.
13.
Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, et al: Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol 2012;107:579-588.
14.
Ramadas AV, Gunesh S, Thomas GA, Williams GT, Hawthorne AB: Natural history of Crohn's disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut 2010;59:1200-1206.
15.
Kariyawasam VC, Selinger CP, Katelaris PH, Jones DB, McDonald C, Barr G, et al: Early use of thiopurines or methotrexate reduces major abdominal and perianal surgery in Crohn's disease. Inflamm Bowel Dis 2014;20:1382-1390.
16.
Chatu S, Subramanian V, Saxena S, Pollok RC: The role of thiopurines in reducing the need for surgical resection in Crohn's disease: a systematic review and meta-analysis. Am J Gastroenterol 2014;109:23-34; quiz 35.
17.
Reich KM, Chang HJ, Rezaie A, Wang H, Goodman KJ, Kaplan GG, et al: The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study. Aliment Pharmacol Ther 2014;40:629-638.
18.
Moore SE, McGrail KM, Peterson S, Raval MJ, Karimuddin AA, Phang PT, et al: Infliximab in ulcerative colitis: the impact of preoperative treatment on rates of colectomy and prescribing practices in the province of British Columbia, Canada. Dis Colon Rectum 2014;57:83-90.
19.
Eaden JA, Abrams KR, Mayberry JF: The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-535.
20.
Jess T, Rungoe C, Peyrin-Biroulet L: Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin Gastroenterol Hepatol 2012;10:639-645.
21.
Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B: Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013;19:789-799.
22.
Jess T, Simonsen J, Jørgensen KT, Pedersen BV, Nielsen NM, Frisch M: Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012;143:375-381.e1; quiz e13-e14.
23.
van den Heuvel T, Jeuring S, Wassink M, Glorie C, Oostenburg L, Romberg-Camps M, et al: Decreased colorectal cancer risk in Dutch ulcerative colitis patients: results from the population based IBD-SL cohort. J Crohns Colitis 2014;8(suppl 1):S61-S62.
24.
Castaño-Milla C, Chaparro M, Gisbert JP: Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014;39:645-659.
25.
Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, et al: Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis 2014;8:5-18.
26.
Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI: Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J Gastroenterol 2005;100:2724-2729.
27.
Canavan C, Abrams KR, Mayberry J: Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment Pharmacol Ther 2006;23:1097-1104.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.